Our finding supports the role of certain myoepithelial markers in tumor progression and suggested that the alteration of the TGF-β pathway may be a potential cause of SPOCK1 dysregulation, conferring poor prognosis in breast cancer. This evidence concerns the gene TGFB1 and neoplasm.